IS2980B - Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl - Google Patents

Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Info

Publication number
IS2980B
IS2980B IS7621A IS7621A IS2980B IS 2980 B IS2980 B IS 2980B IS 7621 A IS7621 A IS 7621A IS 7621 A IS7621 A IS 7621A IS 2980 B IS2980 B IS 2980B
Authority
IS
Iceland
Prior art keywords
amino
cyanoethyl
benzonitrile
dimethylphenyl
pyrimidinyl
Prior art date
Application number
IS7621A
Other languages
English (en)
Other versions
IS7621A (is
Inventor
Philippe Robert Schils Didier
Josephus Maria Willems Joannes
Petrus Anna Maria Jozef Medaer Bart
Therese Jeanne Pasquier Elisabeth
Adriaan Jan Janssen Paul
Heeres Jan
Gerardus George Leenders Ruben
Emile Georges Guillemont Jérome
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31725448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of IS7621A publication Critical patent/IS7621A/is
Publication of IS2980B publication Critical patent/IS2980B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/20—Preparation of carboxylic acid nitriles by dehydration of carboxylic acid amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IS7621A 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl IS2980B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078306 2002-08-09
PCT/EP2003/050366 WO2004016581A1 (en) 2002-08-09 2003-08-07 Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile

Publications (2)

Publication Number Publication Date
IS7621A IS7621A (is) 2004-12-29
IS2980B true IS2980B (is) 2017-09-15

Family

ID=31725448

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7621A IS2980B (is) 2002-08-09 2004-12-29 Aðferðir við að framleiða 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pýrmídínýl]amínó]bensónítríl

Country Status (25)

Country Link
US (3) US7399856B2 (is)
EP (1) EP1529032B1 (is)
JP (1) JP4822707B2 (is)
KR (2) KR101140785B1 (is)
CN (4) CN101481356B (is)
AR (1) AR040964A1 (is)
AU (1) AU2003266413B2 (is)
CA (2) CA2493794C (is)
CL (1) CL2010000284A1 (is)
CY (1) CY1114428T1 (is)
DK (1) DK1529032T3 (is)
EA (1) EA007953B1 (is)
ES (1) ES2422196T3 (is)
HR (1) HRP20050104B1 (is)
IL (1) IL166710A (is)
IS (1) IS2980B (is)
MX (1) MXPA05001541A (is)
MY (1) MY144894A (is)
NO (1) NO330013B1 (is)
NZ (1) NZ538611A (is)
PL (1) PL208533B1 (is)
PT (1) PT1529032E (is)
SI (1) SI1529032T1 (is)
TW (1) TWI314146B (is)
WO (1) WO2004016581A1 (is)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
WO2005123662A1 (en) * 2004-06-18 2005-12-29 Janssen Pharmaceutica N.V. Modified heck reaction
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
PT1632232E (pt) * 2004-09-02 2011-08-02 Janssen Pharmaceutica Nv Sal de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]- 2-pirimidinil]amino]benzonitrilo
SG155885A1 (en) * 2004-09-02 2009-10-29 Janssen Pharmaceutica Nv Furamate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2- pyrimidinyl)amino)benzonitrile
ATE550074T1 (de) * 2004-09-02 2012-04-15 Janssen Pharmaceutica Nv Fumarat aus 4-((4-((4-(2-cyanoethenyl)-2,6- dimethylphenyl amino -2-pyrimidinyl amino benzonitril
US7314962B2 (en) * 2005-04-15 2008-01-01 E. I. Du Pont De Nemours & Co. Alkylation of aromatic compounds
CN101248051B (zh) 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
AP2013006779A0 (en) 2011-04-15 2013-03-31 Emcure Pharmaceuticals Ltd An improved rilpivirine process
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
WO2013170421A1 (zh) * 2012-05-14 2013-11-21 上海迪赛诺药业有限公司 利匹韦林盐酸盐醇化物多晶型物及其制备方法
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
EP2872492B1 (en) * 2012-07-12 2018-01-31 Hetero Research Foundation Process for the preparation of rilpivirine using a novel intermediate
CZ201532A3 (cs) 2015-01-21 2015-02-25 Zentiva, K.S. Způsob výroby vysoce čistého Rilpivirinu a jeho solí
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
MA46563B1 (fr) 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
US20210380540A1 (en) 2018-10-25 2021-12-09 Minakem Process for the preparation of rilpivirine
CN110526873B (zh) * 2019-08-15 2022-09-16 复旦大学 氰乙烯基取代的苯并二芳基嘧啶类化合物及其制备方法和用途
WO2021104487A1 (en) 2019-11-29 2021-06-03 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法
CN112778214A (zh) * 2021-01-13 2021-05-11 安徽贝克联合制药有限公司 用于合成利匹韦林的中间体、其合成方法和利匹韦林的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
DE2861560D1 (en) 1977-11-28 1982-03-04 Barry Boettcher Complexes of bivalent copper, methods of preparation thereof and compositions containing said complexes
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
NZ506679A (en) 1998-03-27 2002-11-26 Janssen Pharmaceutica Nv HIV inhibiting pyrimidine derivatives
BRPI9909191B8 (pt) * 1998-03-27 2021-07-06 Janssen Pharmaceutica Nv derivados de pirimidina inibidores do hiv, seu uso e composição farmacêutica que os compreende
JP2000035628A (ja) 1998-07-16 2000-02-02 Konica Corp ハロゲン化銀写真感光材料
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
ID28376A (id) * 1998-11-10 2001-05-17 Janssen Pharmaceutica Nv Pirimidina yang menghambat replikasi hiv
JP2002539130A (ja) 1999-03-09 2002-11-19 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−オキソ−４，７−ジヒドロ−チエノ［２，３−ｂ］ピリジン−５−カルボキサミド
CA2366932C (en) 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
TR200200763T2 (tr) 1999-09-24 2003-09-22 Janssen Pharmaceutica N.V. Antiviral bileşimler
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
CA2406562C (en) * 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
CZ20032366A3 (en) 2001-03-02 2004-04-14 Smithkline Beecham Corporation Benzophenones as inhibitors of reverse transcriptase
MXPA03008888A (es) * 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
JP2005507874A (ja) * 2001-08-29 2005-03-24 ユーエムディー， インコーポレイテッド 癌治療のための化学療法剤及び膜流出システム阻害剤の経膣送達
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA04010778A (es) * 2002-05-03 2005-03-07 Janssen Pharmaceutica Nv Microemulsiones polimericas.
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Also Published As

Publication number Publication date
NO20050524L (no) 2005-02-01
HK1081527A1 (en) 2006-05-19
NO330013B1 (no) 2011-02-07
DK1529032T3 (da) 2013-07-08
CY1114428T1 (el) 2016-08-31
BR0313545A (pt) 2005-07-12
PL208533B1 (pl) 2011-05-31
IL166710A (en) 2010-12-30
CN102702111A (zh) 2012-10-03
JP2005537303A (ja) 2005-12-08
EA007953B1 (ru) 2007-02-27
CN101481356B (zh) 2012-07-11
HK1129671A1 (en) 2009-12-04
NZ538611A (en) 2007-03-30
EP1529032A1 (en) 2005-05-11
BR0313545B1 (pt) 2021-07-27
HK1174922A1 (en) 2013-06-21
ES2422196T3 (es) 2013-09-09
HRP20050104B1 (hr) 2014-02-14
PT1529032E (pt) 2013-07-11
KR101086678B1 (ko) 2011-11-25
MY144894A (en) 2011-11-30
HRP20050104A2 (en) 2006-03-31
MXPA05001541A (es) 2005-04-19
KR101140785B1 (ko) 2012-05-03
CN102225902B (zh) 2013-04-24
TW200418810A (en) 2004-10-01
AU2003266413A1 (en) 2004-03-03
TWI314146B (en) 2009-09-01
CN101481356A (zh) 2009-07-15
SI1529032T1 (sl) 2013-08-30
CA2686429A1 (en) 2004-02-26
CA2493794A1 (en) 2004-02-26
AU2003266413B2 (en) 2009-04-02
KR20050040906A (ko) 2005-05-03
JP4822707B2 (ja) 2011-11-24
PL373679A1 (en) 2005-09-05
US20080167464A1 (en) 2008-07-10
CL2010000284A1 (es) 2010-08-20
IL166710A0 (en) 2006-01-15
EA200500325A1 (ru) 2005-06-30
CN102702111B (zh) 2014-12-17
US20070191407A1 (en) 2007-08-16
US7563922B2 (en) 2009-07-21
EP1529032B1 (en) 2013-04-24
CN102225902A (zh) 2011-10-26
US7705148B2 (en) 2010-04-27
CA2686429C (en) 2010-11-16
CN100554245C (zh) 2009-10-28
IS7621A (is) 2004-12-29
CN1681774A (zh) 2005-10-12
US20060167253A1 (en) 2006-07-27
CA2493794C (en) 2010-05-25
KR20100127889A (ko) 2010-12-06
US7399856B2 (en) 2008-07-15
WO2004016581A1 (en) 2004-02-26
AR040964A1 (es) 2005-04-27
HK1161869A1 (en) 2012-08-10

Similar Documents

Publication Publication Date Title
IS7621A (is) Aðferðir til þess að búa til 4-[[4-[[4-(2-sýanóetenýl)-2,6-dímetýlfenýl]amínó]-2-pyrimidínýl]amínó]bensónítríl
LTC1632232I2 (lt) 4[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrilo druska
DK2175857T3 (da) Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
DK1610780T3 (da) Cykliske protein-tyrosin-kinasehæmmere
IS8425A (is) Hámörkuð tjáning af HPV 58 L1 í gersveppi
EP1534268A4 (en) TYROSINE KINASE INHIBITORS
EE200300400A (et) Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
DE602004028739D1 (de) Metabolit von quetiapine
DK1578731T3 (da) Fremgangsmåde til fremstilling af pyrimidinforbindelser
ATE381541T1 (de) Aminotetralinderivate, antagonisten von muscarinrezeptoren
CR9031A (es) Clorhidrato de 4-((4-((4-2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)amino)benzonitrilo
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
AP2487A (en) Fumarate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
DK1419160T3 (da) Fremgangsmåde til fremstilling af 6-(4-chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-eddikesyre
IL164377A (en) Methods of preparation of 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
DK1569695T3 (da) Antisense-modulering af apolipoprotein-b-ekspression
ITRM20010736A1 (it) Impianto osteointegrato di lunghezza aggiustabile e un kit per la suapreparazione.
UA7546S (uk) Готова страва, що складається з двох компонентів